年5月11日，英国《柳叶刀肿瘤学分册》在线发表了意大利、波兰、韩国、中国台湾、西班牙、巴西、加拿大、俄罗斯、泰国、英国（罗氏、阿斯利康）的多中心非盲Ⅱ期随机研究（NeoSphere）5年分析：帕妥珠单抗和曲妥珠单抗新辅助治疗局部晚期、炎性或早期HER2阳性乳腺癌患者。

　　该研究发现，虽然随访5年无进展生存和无病生存的置信区间太大且重叠，但是支持主要终点（病理学完全缓解）并表明曲妥珠单抗和多西他赛联合帕妥珠单抗新辅助治疗是有益的。此外，总的病理学完全缓解可能是早期HER2阳性乳腺癌长期预后的早期指标。

LancetOncol.May11.[Epubaheadofprint]

5-yearanalysisofneoadjuvantpertuzumabandtrastuzumabinpatientswithlocallyadvanced,inflammatory,orearly-stageHER2-positivebreastcancer(NeoSphere):amulticentre,open-label,phase2randomisedtrial.

LucaGianni,TadeuszPienkowski,Young-HyuckIm,Ling-MingTseng,Mei-ChingLiu,AnaLluch,El?bietaStaros?awska,JuandelaHaba-Rodriguez,Seock-AhIm,JoseLuizPedrini,BrigittePoirier,PaoloMorandi,VladimirSemiglazov,VichienSrimuninnimit,GiuliaValeriaBianchi,DomenicoMagazzù,VirginiaMcNally,HannahDouthwaite,GrahamRoss,PinucciaValagussa.

OncologiaMedica,SanRaffaeleCancerCentre,Milan,Italy.

PostgraduateMedicalEducationCentre,Warsaw,Poland.

SamsungMedicalCentre,Seoul,SouthKorea.

Taipei-VeteransGeneralHospital,NationalYang-MingUniversity,Taipei,Taiwan.

KooFoundationSunYat-SenCancerCenter,Taipei,Taiwan.

HospitalClínicoUniversitario,INCLIVAHealthResearchInstitute,UniversityofValencia,Valencia,Spain.

StJohnsCancerCentre,Lublin,Poland.

MaimonidesInstituteofBiomedicalResearch,ReinaSofíaHospital,UniversityofCórdoba,Córdoba,Spain.

CancerResearchInstitute,SeoulNationalUniversityCollegeofMedicine,Seoul,SouthKorea.

HospitalNossaSenhoradaConcei??o,HospitalErnestoDornelles,PortoAlegre,Brazil.

H?pitalduSaint-Sacrément,CentreHospitalierAffiliéUniversitairedeQuébec,Québec,Canada.

OspedaledellAngeloMestre,OspedaleSanGiovanniePaoloVenezia,Venice,Italy.

NNPetrovResearchInstituteofOncology,StPetersburg,Russia.

SirirajHospital,Bangkok,Thailand.

FondazioneIRCCSIstitutoNazionaleTumori,Milan,Italy.

FondazioneMichelangelo,Milan,Italy.

RocheProductsLimited,Welwyn,UK.

AstraZeneca,Melbourn,Cambridge,UK.

Background:IntheprimaryanalysisoftheNeoSpheretrial,patientsgivenneoadjuvantpertuzumab,trastuzumab,anddocetaxelshowedasignificantlyimprovedpathological